Epithalon vs Epitalon: Same Peptide, Two Spellings. The Name That Means Something Different Is Epithalamin, and Most of the Human Data Belong to It.
Epithalon vs epitalon is not a comparison between two peptides. Epithalon and epitalon are two spellings of the same synthetic tetrapeptide, Ala-Glu-Asp-Gly, usually shortened to AEDG. A 2025 review in the International Journal of Molecular Sciences states it directly: epitalon is also known as epithalon or epithalone. The FDA uses the names interchangeably as well. The comparison that does matter is between epitalon and epithalamin, a polypeptide extract of the pineal gland that epitalon was modeled on. The FDA treats those two as different substances, and the best-known human mortality data come from epithalamin, not from the synthetic peptide sold online. This article sorts out the names, the chemistry and which evidence belongs to which compound.
Key Takeaways: Epithalon vs Epitalon
Epithalon and epitalon are the same molecule: the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG), with the molecular formula C14H22N4O9 and a molecular weight of 390.35 g/mol, according to FDA's 2026 evaluation of the substance. Epithalamin is a different substance. The FDA describes epithalamin as a polypeptide complex extracted from the pineal gland and epitalon as a tetrapeptide synthesized from the study of epithalamin's amino acid content. The best-known human outcome report in this research area, 266 elderly people followed for 6 to 8 years, tested epithalamin and thymalin, not synthetic epitalon (Khavinson and Morozov, Neuro Endocrinology Letters, 2003). In female mice, synthetic Epitalon did not change mean lifespan but raised the lifespan of the last 10% of survivors by 13.3% (Anisimov and colleagues, Biogerontology, 2003). FDA reviewers found three studies in which epitalon was given to humans, no clinical studies assessing its safety and no pharmacokinetic data, and staff proposed against adding it to the compounding bulks list. At the July 2026 advisory committee meeting, the committee still voted 7-5, with one abstention, to recommend epitalon for the list for insomnia. The vote is advisory, and FDA makes the final decision.
What FDA Found When It Searched for Human Epitalon Data
Counts reported in FDA's evaluation of epitalon free base and epitalon acetate for the July 23 to 24, 2026 Pharmacy Compounding Advisory Committee. FAERS was searched through December 8, 2025. Zero adverse event reports reflects voluntary reporting, not proof of safety.
Is epitalon the same as epithalon?
Yes, epitalon is the same as epithalon. Both names refer to one synthetic peptide made of four amino acids in a fixed order: alanine, glutamic acid, aspartic acid and glycine, written Ala-Glu-Asp-Gly or AEDG. Araj and colleagues, in a 2025 review in the International Journal of Molecular Sciences, open with the line that epitalon is also known as epithalon or epithalone. The FDA agrees. Its evaluation for the Pharmacy Compounding Advisory Committee, held July 23 to 24, 2026, states that epitalon is also known as epithalon and by its amino acid components, and the reviewers use the terms interchangeably. The FDA's substance registry lists epitalon under the unique ingredient identifier O65P17785G. Both spellings, with and without the h, appear in peer-reviewed papers, including papers from the Russian group that developed the peptide; papers co-authored by Vladimir Khavinson used epithalon in a 2001 title and Epitalon in a 2003 title. Epithalone is a third variant of the same name. None of these spellings signals a different molecule, a different purity grade or a different product.
Where did the names epithalon and epitalon come from?
The names epithalon and epitalon come from epithalamin, the pineal extract the peptide was designed to imitate. The epithalamus is the region of the brain that contains the pineal gland, and epithalamin was the name given to a peptide preparation extracted from bovine pineal tissue. According to the FDA's 2026 evaluation, epitalon was first synthesized in the late 1980s by researchers under the direction of Professor Vladimir Khavinson in Saint Petersburg, Russia. Araj and colleagues describe the process: the tetrapeptide was synthesized based on the amino acid composition of epithalamin, the bovine pineal gland extract. The FDA describes epitalon as a synthetic peptide that may be the putative active component of epithalamin. That history explains why the names look so similar. Epithalamin is the parent extract, and epitalon or epithalon is the short synthetic copy. Goncharova and colleagues, in Experimental Gerontology in 2005, called epitalon a synthetic analogue of the pharmacopoeia drug epithalamin.
What is the difference between epitalon and epithalamin?
Epitalon is a single defined molecule of four amino acids, while epithalamin is a mixture of peptides extracted from animal pineal glands. That is the one real difference hiding inside the epithalon vs epitalon search. The FDA draws the line explicitly. Nominators who asked FDA to allow epitalon in compounding listed epithalamin as another common name for it, and the FDA rejected that equivalence: it considers epitalon and epithalamin different substances, and epithalamin is not listed as a synonym for epitalon in the FDA's substance registry. Korkushko and colleagues, writing in Advances in Gerontology in 2007, used the same distinction, describing epithalamin as a complex of peptides isolated from the pineal gland and epitalon as a synthetic tetrapeptide. The two have been compared directly in animals. Khavinson and colleagues reported in 2001 that epithalamin and epithalon produced similar effects on the spleen of old rats whose pineal glands had been removed (Bulletin of Experimental Biology and Medicine). Similar effects in one rat tissue do not make the two interchangeable, and a result for one cannot simply be assigned to the other.
Epithalamin, the Pineal Extract, in Three Species
Decrease in mortality rate with the pineal extract epithalamin, not the synthetic tetrapeptide. The rate did not change in SHR mice (Anisimov and colleagues, Mechanisms of Ageing and Development, 1998).
Why does the epitalon vs epithalamin distinction matter for the evidence?
The distinction matters because the most cited human longevity numbers come from epithalamin, the extract, not from synthetic epitalon. Readers who see those numbers on a product page for epithalon are often looking at data from a different substance. The main human report is Khavinson and Morozov, Neuro Endocrinology Letters, 2003. It described 266 elderly people observed for 6 to 8 years, with the peptide preparations given during the first 2 to 3 years. The authors reported mortality 1.6 to 1.8 times lower in the epithalamin group, 2.0 to 2.1 times lower with thymalin (a thymus extract), 2.5 times lower with both, and 4.1 times lower in a group given both every year for 6 years, compared with controls. The abstract does not describe randomization, and the work came from the same institute that developed the products. The animal lifespan record splits the same way. Anisimov and colleagues reported in 1998 that epithalamin lowered the mortality rate by 52% in fruit flies, 52% in rats and 27% in C3H/Sn mice, and did not change it in SHR mice (Mechanisms of Ageing and Development). When the same group tested synthetic Epitalon in SHR mice in 2003, mean lifespan did not change. The two compounds were tested in different experiments, and their results should be reported under their own names.
The Human Mortality Data Belong to the Extract
Fold reduction in mortality versus control reported for 266 elderly people followed for 6 to 8 years, with peptides given in the first 2 to 3 years. Lower and upper ends of each reported range shown. No group received synthetic epitalon (Khavinson and Morozov, Neuro Endocrinology Letters, 2003).
- Reported (low end)
- Reported (high end)
What has synthetic epitalon actually been shown to do?
Synthetic epitalon has mainly been studied in cells and animals, and the results are mixed rather than uniformly positive. Araj and colleagues note that over the last 25 years epitalon has been studied with in vitro, in vivo and in silico methods, and that physical and structural studies of the peptide remain limited. The key mouse lifespan study is Anisimov and colleagues, Biogerontology, 2003. Female SHR mice, 54 per group, received 1.0 microgram of Epitalon by injection on 5 consecutive days every month from 3 months of age until death. Epitalon did not change mean lifespan, food intake or body weight. It increased the lifespan of the last 10% of survivors by 13.3%, increased maximum lifespan by 12.3%, cut chromosome aberrations in bone marrow cells by 17.1% and inhibited leukemia 6.0-fold, with no change in total tumor incidence. In old rhesus monkeys aged 20 to 27 years, epitalon lowered basal glucose and insulin and raised night-time melatonin, with no effect in young monkeys aged 6 to 8 years (Goncharova and colleagues, Experimental Gerontology, 2005). In cell culture, Al-Dulaimi and colleagues reported in Biogerontology in 2025 that epitalon lengthened telomeres in normal cells by raising hTERT and telomerase, and in breast cancer cell lines through a separate pathway called ALT. Cell and animal results describe mechanisms; they are not evidence of benefit in people. This site's longer epitalon guide, Epithalon Peptide for Men: The Complete Telomere and Longevity Guide, covers the telomere research in more depth.
Synthetic Epitalon in Mice: No Change in Average Lifespan
Percent change versus saline controls in female SHR mice, 54 per group, injected with 1.0 microgram of Epitalon on 5 consecutive days every month from 3 months of age (Anisimov and colleagues, Biogerontology, 2003).
How much human research exists on epithalon?
Very little human research exists on synthetic epithalon. When the FDA searched the literature for its 2026 evaluation, reviewers found three studies in which epitalon was given to humans. Two gave the peptide under the tongue to night-shift workers to study melatonin and circadian genes, and one gave it as an injection near the eye in patients with retinitis pigmentosa. The most detailed is Ivko and colleagues, 2021, as summarized by the FDA. Seventy-five healthy women aged 40 to 50, mostly night-shift workers, were sorted by melatonin output, and the 40 with low levels were split into placebo and AEDG spray groups for 20 days, with 0.5 mg of peptide a day. A urinary melatonin breakdown product rose 1.7-fold on AEDG and did not change on placebo. The authors reported positive changes in well-being in 83% of the peptide group versus 25% on placebo, but the FDA noted that blinding was not specified and the well-being measure was not described. Epitalon also received an orphan drug designation for retinitis pigmentosa on September 2, 2010, which was withdrawn on January 6, 2016, according to the FDA document. For the melatonin side of this research, see Pineal Gland, Melatonin and Epitalon on this site.
The Only Placebo-Controlled Human Study of the Tetrapeptide
Percent of night-shift women aged 40 to 50 with low melatonin output reporting positive changes in well-being after 20 days of sublingual AEDG (0.5 mg a day) or placebo spray. Blinding was not specified and the measure was not described (Ivko and colleagues, 2021, as summarized in FDA's July 2026 compounding committee briefing).
Is epithalon safe, and what did the FDA conclude?
Epithalon's safety in humans has not been established, according to the FDA. Reviewers concluded that there are no clinical data to support the safety of epitalon free base or epitalon acetate when used in humans. No pharmacokinetic data were found. A search of the FDA Adverse Event Reporting System through December 8, 2025 retrieved no reports, which the FDA cautions reflects voluntary reporting rather than proof of safety. The FDA raised three specific concerns. First, immunogenicity: peptides injected under the skin can provoke an immune response, and aggregation or peptide-related impurities could raise that risk. Second, cancer risk in theory: because epitalon has been reported to activate telomerase and lengthen telomeres, reviewers wrote that continuous exposure through the lifespan could enable cells to evade senescence, and no 2-year carcinogenicity studies were found. Third, quality: there is no USP monograph for epitalon, and it is not a component of any FDA-approved drug. FDA staff proposed not adding epitalon to the 503A bulks list, the list of substances pharmacies may use for compounding. At the July 2026 meeting, the advisory committee disagreed and voted 7-5, with one member abstaining, to recommend placing epitalon on the list for insomnia, according to RAPS Regulatory Focus. The vote is a recommendation, and FDA will make the final decision.
Does the spelling on a vial tell you what is inside?
No, the spelling on a vial says nothing about what is inside it. Whether a label reads epithalon, epitalon or epithalone, the name is a common name, not an official drug name, and the FDA flags that as a safety problem in its own right. The FDA's 2026 evaluation states that epitalon is a common name and not a United States Adopted Name, and that the agency has encountered multiple salts and derivatives, including different active moieties, sold commercially under the same common name. The FDA warned that inconsistent naming is a safety risk because patients may be dosed with a different substance than the physician ordered. The salt form is a concrete example. Epitalon free base and epitalon acetate are different active pharmaceutical ingredients, according to the FDA, and the nominators who asked FDA to allow epitalon in compounding gave inconsistent information about which one they meant. A product sold under either spelling could be the free base, the acetate or something else, and only a certificate of analysis that tests identity, purity, impurities and endotoxins can show which.
What should men take away from the epithalon vs epitalon question?
Men researching epithalon vs epitalon can stop comparing the two spellings: they name the same AEDG tetrapeptide. The useful comparison is between synthetic epitalon and epithalamin, the pineal extract, because the human mortality figures most often quoted for epithalon come from epithalamin and thymalin. For synthetic epitalon itself, the record is mostly cell and animal work from a small number of research groups, a few small human studies, a mouse lifespan study in which mean lifespan did not change, and an FDA review that found no clinical safety data. The July 2026 committee vote in favor of compounding for insomnia is a regulatory development, not a finding that the peptide works for aging. Anyone weighing epitalon should treat it as an unapproved drug, ask which salt form and which compound a product actually contains, and discuss it with a physician who knows that the evidence is thin.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Does Telomere Length Determine Lifespan? Short Telomeres Track With Earlier Death. The Genetics Say Longer Ones Raise Cancer Risk.
Does telomere length determine lifespan? Short telomeres track with earlier death, yet genetic studies show longer ones raise the risk of several cancers.
Low-Dose Aspirin Added 8 Percent to Male Mouse Lifespan. In 19,114 Healthy Older Adults, It Added No Healthy Years and Deaths Ran Higher.
Does low-dose aspirin help longevity? It extended male mouse lifespan 8%, but the ASPREE trial in 19,114 healthy older adults found no gain and more bleeding.
What Is the Difference Between Peptides and Copper Peptides? A Copper Peptide Is a Peptide Holding a Metal Ion, and the Skin Evidence Splits Along That Line
What is the difference between peptides and copper peptides? A copper peptide is a peptide bound to copper. How GHK-Cu differs and what skin trials show.